Most Breast Cancer Patients with T1-2 Tumors and One to Three Positive Lymph Nodes Do Not Need Postmastectomy Radiotherapy

[1]  David Cameron,et al.  11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial , 2017, The Lancet.

[2]  S. Edge,et al.  Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  E. van Limbergen,et al.  Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer. , 2015, The New England journal of medicine.

[4]  H. Struikmans,et al.  Regional Nodal Irradiation in Early-Stage Breast Cancer. , 2015, The New England journal of medicine.

[5]  M. Morrow,et al.  The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy , 2015, Annals of Surgical Oncology.

[6]  J. Bogaerts,et al.  Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. , 2014, The Lancet. Oncology.

[7]  W. Woodward,et al.  Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. , 2014, International journal of radiation oncology, biology, physics.

[8]  Cynthia L. Miller,et al.  The impact of radiation therapy on the risk of lymphedema after treatment for breast cancer: a prospective cohort study. , 2014, International journal of radiation oncology, biology, physics.

[9]  S. Takashima,et al.  Are there high-risk subgroups for isolated locoregional failure in patients who had T1/2 breast cancer with one to three positive lymph nodes and received mastectomy without radiotherapy? , 2014, Breast Cancer.

[10]  K. Chung,et al.  A Systematic Review of Morbidity Associated with Autologous Breast Reconstruction Before and After Exposure to Radiotherapy: Are Current Practices Ideal? , 2014, Annals of Surgical Oncology.

[11]  X. Chen,et al.  Irradiation after surgery for breast cancer patients with primary tumours and one to three positive axillary lymph nodes: yes or no? , 2013, Current oncology.

[12]  M. Stempel,et al.  Selection Criteria for Postmastectomy Radiotherapy in T1–T2 Tumors with 1 to 3 Positive Lymph Nodes , 2013, Annals of Surgical Oncology.

[13]  P. Hall,et al.  Risk of ischemic heart disease in women after radiotherapy for breast cancer. , 2013, The New England journal of medicine.

[14]  C. Reddy,et al.  Impact of postmastectomy radiation on locoregional recurrence in breast cancer patients with 1-3 positive lymph nodes treated with modern systemic therapy. , 2012, International journal of radiation oncology, biology, physics.

[15]  A. Goldhirsch,et al.  Mastectomy without radiotherapy: outcome analysis after 10 years of follow-up in a single institution , 2012, Breast Cancer Research and Treatment.

[16]  S. Shirvani,et al.  Impact of evidence‐based clinical guidelines on the adoption of postmastectomy radiation in older women , 2011, Cancer.

[17]  Jack Cuzick,et al.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. , 2010, The Lancet. Oncology.

[18]  C. Horng,et al.  Radiotherapy can decrease locoregional recurrence and increase survival in mastectomy patients with T1 to T2 breast cancer and one to three positive nodes with negative estrogen receptor and positive lymphovascular invasion status. , 2010, International journal of radiation oncology, biology, physics.

[19]  H. Kuerer,et al.  Present-Day Locoregional Control in Patients with T1 or T2 Breast Cancer with 0 and 1 to 3 Positive Lymph Nodes After Mastectomy Without Radiotherapy , 2010, Annals of Surgical Oncology.

[20]  D. Cowen,et al.  Immediate post-mastectomy breast reconstruction followed by radiotherapy: risk factors for complications , 2010, Breast Cancer Research and Treatment.

[21]  Barbara L. Smith,et al.  Chest wall radiotherapy: middle ground for treatment of patients with one to three positive lymph nodes after mastectomy. , 2009, International journal of radiation oncology, biology, physics.

[22]  A. Taghian,et al.  Patterns and risk factors of locoregional recurrence in T1-T2 node negative breast cancer patients treated with mastectomy: implications for postmastectomy radiotherapy. , 2009, International journal of radiation oncology, biology, physics.

[23]  T. Möller,et al.  Radiotherapy and tamoxifen after mastectomy in postmenopausal women -- 20 year follow-up of the South Sweden Breast Cancer Group randomised trial SSBCG II:I. , 2007, European journal of cancer.

[24]  J. Overgaard,et al.  Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[25]  H. Bartelink,et al.  Quality assurance in breast cancer: EORTC experiences in the phase III trial on irradiation of the internal mammary nodes. , 2007, European journal of cancer.

[26]  E. Yıldırım,et al.  Local recurrence in breast carcinoma patients with T(1-2) and 1-3 positive nodes: indications for radiotherapy. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[27]  J. Cuzick,et al.  Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study , 2007, BMC Cancer.

[28]  A. Taghian,et al.  Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Collins,et al.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[30]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[31]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[32]  E. Berthelet,et al.  Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy. , 2005, International journal of radiation oncology, biology, physics.

[33]  G. Hortobagyi,et al.  Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  H. Mouridsen,et al.  Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer co-operative Group DBCG 82B Trial. , 1999, European journal of cancer.

[35]  R. Gray,et al.  Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  B. Rasmussen,et al.  Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial , 1999, The Lancet.

[37]  L. Rutqvist,et al.  Long-term cardiac morbidity and mortality in a randomized trial of pre- and postoperative radiation therapy versus surgery alone in primary breast cancer. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[38]  C. Greenberg,et al.  Temporal Trends in Postmastectomy Radiation Therapy and Breast Reconstruction Associated With Changes in National Comprehensive Cancer Network Guidelines. , 2016, JAMA oncology.

[39]  R. Gopal.  The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy: Lanning RM, Morrow M, Riaz N, et al (Memorial Sloan Kettering Cancer Ctr, New York) Ann Surg Oncol 22:2517-2525, 2015§ , 2016 .

[40]  J. Overgaard,et al.  Second primary cancers after adjuvant radiotherapy in early breast cancer patients: a national population based study under the Danish Breast Cancer Cooperative Group (DBCG). , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[41]  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials , 2012 .